Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 24.43M P/E - EPS this Y 24.20% Ern Qtrly Grth -
Income -19.88M Forward P/E -1.54 EPS next Y 30.80% 50D Avg Chg -26.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -39.00%
Dividend N/A Price/Book 0.46 EPS next 5Y - 52W High Chg -61.00%
Recommedations 2.00 Quick Ratio 2.15 Shares Outstanding 26.56M 52W Low Chg 6.00%
Insider Own 3.96% ROA -28.14% Shares Float 235.63M Beta 0.57
Inst Own 9.16% ROE -49.09% Shares Shorted/Prior 223K/315.36K Price 1.08
Gross Margin - Profit Margin - Avg. Volume 77,466 Target Price 9.67
Oper. Margin - Earnings Date - Volume 79,617 Change -2.70%
About Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech Ltd. News
06:00 AM Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
03/14/24 Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
03/05/24 Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
02/27/24 Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
02/13/24 Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
02/01/24 Purple Biotech Reaches Recommended Phase 2 Dose for NT219
12/20/23 Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
12/14/23 Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
11/21/23 Purple Biotech Reports Third Quarter 2023 Financial Results
11/02/23 Purple Biotech Fortifies NT219 Patent Protection
10/19/23 Purple Biotech Announces Closing of $5 Million Registered Direct Offering
10/17/23 Purple Biotech Announces $5 Million Registered Direct Offering
10/06/23 Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
10/03/23 Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
09/21/23 Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
08/22/23 Purple Biotech Reports Second Quarter 2023 Financial Results
07/11/23 Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
05/16/23 Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
04/25/23 Purple Biotech Debuts Scientific Advisory Board
04/19/23 Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
PPBT Chatroom

User Image WalkingDread Posted - 16 minutes ago

$PPBT 3/4 stable disease in low dose monotherapy (3 - 24mg/kg)reported in 2022. Ill stick around to see what current dosing(100mg) produces.

User Image sbrino Posted - 21 minutes ago

$PPBT c tres is on here an awful lot, wonder how man shares he has? 😽

User Image Ctres06 Posted - 32 minutes ago

$PPBT volume is huge! Must be the great news we got this morning.

User Image Sleepwhndead Posted - 44 minutes ago

$PPBT they need to show something AMAZING and soon! Cause if not, we won’t last long enough before a RS is forced to wait for something good

User Image hughjazz15 Posted - 57 minutes ago

$PPBT my prediction, good news, stonk go down

User Image Stocksidobet Posted - 59 minutes ago

$PPBT we gonna leavege this thick dick on you 😂😂😂

User Image FBP Posted - 1 hour ago

$PPBT if it aint topline market won't care I'm betting. Good to show this at the upcoming conference but the needle needs to be bigger is my guess.

User Image Sleepwhndead Posted - 1 hour ago

$PPBT we were also told “rapid ROI” and “monumental year” for a long time lol Oh and “cash runway” All have been lies

User Image YamiDawg Posted - 1 hour ago

$PPBT Scanners in pre. Lol. Go bears. 10%.

User Image Dr_HIM Posted - 1 hour ago

$PPBT

User Image Covence Posted - 1 hour ago

$PPBT NEW DATA 🚨 “At AACR 2024 we will present new data related to NT219. We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence.”

User Image LuckyBoy369 Posted - 1 hour ago

$PPBT Be Ready for spike Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, "At AACR 2024 we will present new data related to NT219. We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence

User Image allgoodstill Posted - 1 hour ago

$PPBT Hopefully some of his real 12k followers will notice something of interest here.🤷‍♂️

User Image PPBT4LYFE Posted - 1 hour ago

$PPBT I didn’t realize it was preclinical again. Gdammit.

User Image LuckyBoy369 Posted - 1 hour ago

$PPBT Major pump incoming. All Abroad We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.

User Image PPBT4LYFE Posted - 1 hour ago

$PPBT I’m not a playa I just crush a lot.

User Image roachfood Posted - 1 hour ago

$PPBT “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.” Key word for me here is “leveraging” and what route they take to do that.

User Image lilc1477 Posted - 1 hour ago

$PPBT This is long overdue for a pump. $15 million market cap for a company with multiple Phase II drugs in hard to treat cancers with unmet medical needs. This deserves a little love

User Image YamiDawg Posted - 1 hour ago

$PPBT

User Image vinland Posted - 1 hour ago

$PPBT Now to make it happen, talk is cheap. Gil last year - I think our future will primarily involve leveraging data that we generate to be able to raise more capital and expand the programs or add assets. Gil today - We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.

User Image Ctres06 Posted - 1 hour ago

$PPBT those abstracts are not going to do anything for the stock price. It's embarrassing that we have been here this long and we are presenting preclinical data and phase 1 biomarker data. No actual clinical data coming.

User Image KITOVLI Posted - 1 hour ago

$PPBT $1

User Image Sleepwhndead Posted - 2 hours ago

$PPBT if this next conference and data presentation isn’t INSANELY AMAZING, then just start preparing for the REVERSE SPLIT… we are running out of money with almost no tutes interested in being involved with us. If the data does nothing for us and it’s not mind blowing, the next reverse split will wipe out current shareholders as it’ll be the 2nd one for most

User Image Stocktelligence Posted - 2 hours ago

$PPBT me like it We show for the first time the potential of NT219 to effectively suppress cancer stem cells (CSC), a critical cell population for tumor propagation, characterized by self-renewal and multipotency, and known to promote resistance and tumor recurrence. In addition, synergistic effect of NT219 and mKRAS inhibitors is demonstrated, suggesting a novel mechanism to combat resistance to both KRASG12Cand KRAS KRASG12D inhibitors in lung cancer and pancreatic cancers, respectively, both aggressive diseases with unmet medical need. In another presentation, we show the results of translational research in our Phase 1 study, suggesting activated IGF1R and STAT3 as potential biomarkers for the treatment with NT219

User Image Watcher76 Posted - 2 hours ago

$PPBT Purple is looking a lot better today!

User Image DonCorleone77 Posted - 2 hours ago

$PPBT Purple Biotech to present data on NT219 at AACR 2024 Purple Biotech announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research, AACR, annual meeting which takes place April 5-11, 2024, in San Diego, California. "The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers. These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219's attributes," stated Gil Efron, Chief Executive Officer of Purple Biotech. "We look forward to leveraging these data as we move forward with the clinical evaluation of NT219."

User Image Richgreenz Posted - 2 hours ago

$PPBT 🥹

User Image Wkdwalker Posted - 2 hours ago

$PPBT data we are waiting for 😎

User Image kckc88 Posted - 3 hours ago

$PPBT I thought it was gonna be cm24 data we would be presenting in April 🤔 let’s goooooo!!!!

User Image ksmithwnc Posted - 3 hours ago

$PPBT this one seems significant

Analyst Ratings
Chardan Capital Buy Mar 7, 24
HC Wainwright & Co. Buy Mar 5, 24
HC Wainwright & Co. Buy Feb 27, 24
HC Wainwright & Co. Buy Nov 21, 23
HC Wainwright & Co. Buy Aug 31, 23
HC Wainwright & Co. Buy Aug 30, 23
JonesTrading Buy Jul 21, 23
HC Wainwright & Co. Buy May 17, 23
Chardan Capital Buy May 17, 23